Leveraging the unique co-expression of PD-L1 and CD47 on tumor-infiltrating Tregs, our aptamer-siRNA chimera achieves cell-type-selective delivery of RNA interference, combining immune checkpoint blockade with gene silencing in a single molecule. The gene discussed is CD47; the disease is neoplasm.